Carcinoma

In the phase 3 SPOTLIGHT trial (NCT03504397), 565 patients with gastroesophageal junction adenocarcinoma were randomized to receive either zolbetuximab combined with mFOLFOX6 (n=283) or placebo with m… (full text at CIViC)

PMID 37068504 · Shitara et al., 2023 · Open in CIViC

In a targeted sequencing study of 28 patients with sarcomatoid hepatocellular carcinoma (SHC), one case hand an NTRK1 fusion involving the intergenic region downstream of CRABP2 and NTRK1 exon 9 (NM_0… (full text at CIViC)

PMID 36741696 · Jia et al., 2022 · Open in CIViC

Ablation of the CBP paralog p300/EP300 has been identified as syntheticaly lethal in in CBP-knockout and CBP-deficient cancer cells and induced a G1-S cell-cycle arrest, followed by apoptosis. Genome-… (full text at CIViC)

PMID 26603525 · Ogiwara et al., 2016 · Open in CIViC

CRKL is an oncogene in a subset of NSCLC. Overexpression of CRKL induces cell transformation and resistance to epidermal growth factor receptor inhibitor treatment and suggest that therapeutic interve… (full text at CIViC)

PMID 22586683 · Cheung et al., 2011 · Open in CIViC

This work shows that across multiple cancer types, responses were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune c… (full text at CIViC)

PMID 25428504 · Herbst et al., 2014 · Open in CIViC

This study shows that across multiple cancer types, responses were observed in patients with tumours expressing high levels of PD-L1, especially when PD-L1 was expressed by tumour-infiltrating immune… (full text at CIViC)

PMID 25428504 · Herbst et al., 2014 · Open in CIViC

CXCR4, a stromal-derived-factor-1 specific chemokine receptor, is highly expressed in non-small cell lung cancer (NSCLC) tissues and participates in cancer progression by regulating cell growth, apopt… (full text at CIViC)

PMID 27922681 · Xie et al., 2017 · Open in CIViC

CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resis… (full text at CIViC)

PMID 20651371 · Xie et al., 2010 · Open in CIViC

In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

Ba/F3 cells expressing the G774V mutation were sensitive to the tyrosine kinase inhibitor dasatinib while wild-type expressing cells were not, as measured in a proliferation assay.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

The NCI-H2286 lung squamous cell carcinoma cell line, containing the DDR2 I638F mutation was shown to be sensitive (IC50 139nm) to dasatinib in-vitro. Dasatanib sensitivity was demonstrated in-vivo us… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

The HCC-366 lung adenosquamous carcinoma cell line, containing the DDR2 L239R mutation was shown to be sensitive (IC50 140nm) to dasatinib in-vitro. The authors were unable to establish tumors using t… (full text at CIViC)

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

Validating predominant overexpression of DDR2 in 554 head and neck squamous cell carcinoma (HNSCC) patients indicated the potentiality of utilizing dasatinib as a DDR2 inhibitor. From these patients, … (full text at CIViC)

PMID 27434411 · von Mässenhausen et al., 2016 · Open in CIViC

In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response.

PMID 22328973 · Hammerman et al., 2011 · Open in CIViC

The primary tumor of A patient with head and neck squamous cell carcinoma with lung metastasis was not surgically resectable. Initial treatments led to stable disease and progression after 1 year. The… (full text at CIViC)

PMID 31011208 · Yang et al., 2019 · Open in CIViC

In a phase II trial, patients with DLL3-expressing small cell lung carcinoma were treated with rovalpituzumab tesirine. Only patients with 1% or more tumor cells expressing DLL3 were enrolled. In this… (full text at CIViC)

PMID 31506387 · Morgensztern et al., 2019 · Open in CIViC

74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma received at least one dose of rovalpituzumab tesirine in a phase 1 trial. 11 (18%) of 60 assessable patients … (full text at CIViC)

PMID 27932068 · Rudin et al., 2017 · Open in CIViC

RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional … (full text at CIViC)

PMID 25698061 · Graham et al., 2015 · Open in CIViC

A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion wa… (full text at CIViC)

PMID 24578576 · Honeyman et al., 2014 · Open in CIViC

High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric … (full text at CIViC)

PMID 21458988 · Mutze et al., 2011 · Open in CIViC

A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome ana… (full text at CIViC)

PMID 31871216 · Majounie et al., 2020 · Open in CIViC

3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amp… (full text at CIViC)

PMID 25677871 · Ansell et al., 2016 · Open in CIViC

A total of 106 Chinese NSCLC patients who had failed at least one chemotherapy regimen received gefitinib 250 mg once daily. Patients with EGFR mutations had a significantly higher overall response ra… (full text at CIViC)

PMID 19020901 · Xu et al., 2009 · Open in CIViC

In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including wether or not administrati… (full text at CIViC)

PMID 23749122 · Locatelli-Sanchez et al., 2013 · Open in CIViC

Out of a group of 19 EGFR exon 20 insertion NSCLC patients, 3 patients had EGFR M766_A767insASV mutation. One patient was 69 year old female neversmoker lung adenocarcinoma patient was given erlotini… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In this study, 4 patients with an EGFR exon 19 insertion and 6 patients with an EGFR exon 20 insertion (A763_Y764insFQEA) were enrolled. Hospital. Among patients with an exon 19 insertion, 3 received … (full text at CIViC)

PMID 28089594 · Lin et al., 2017 · Open in CIViC

In an in vitro study, MCF-7 cells expressing the EGFR A767_V769dup mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 10 nM. In comparison, cells e… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced prog… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR A859T mutation, EGFR A859T was reported to be sensitive to erlotinib treatment. The patient was initially treated with standard chemotherapy and subsequ… (full text at CIViC)

PMID 21317745 · Le Maignan et al., 2011 · Open in CIViC

In an in vitro study, a MCF-7 cell line expressing EGFR A859T demonstrated reduced sensitivity to erlotinib treatment compared to MCF-7 cells expressing EGFR L858R (a known sensitizing mutation to EGF… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

NSCLC with EGFR activating alterations are frequently treated with the tyrosine kinase inhibitor, osimertinib. Though initially very effective, cancers cells often develop resistance to osimertinib th… (full text at CIViC)

PMID 37481710 · Lu et al., 2023 · Open in CIViC

The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tum… (full text at CIViC)

PMID 16943533 · Chung et al., 2006 · Open in CIViC

In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.

PMID 20840671 · Marx et al., 2010 · Open in CIViC